Matheke M L, Kessler G, Chan K M
Department of Pathology, Washington University School of Medicine, St. Louis, MO 63110.
Clin Chem. 1987 Nov;33(11):2109-10.
A 62-year-old woman receiving chemotherapy with etoposide showed discrepant uric acid values as measured by a direct phosphotungstic acid (PTA) method (150 mg/L) compared with a uricase technique (40 mg/L). After ultrafiltration, the positive interference for the direct PTA method was retained in the protein fraction, but not in the filtrate. Adding exogenous etoposide to drug-free serum confirmed this interference for the direct PTA method, but not for the uricase procedure or a PTA technique preceded by dialysis. Decisions for aggressive patient management are often based on the magnitude of hyperuricemia. We do not recommend that the direct phosphotungstic acid method be used to measure uric acid in patients receiving etoposide.
一名接受依托泊苷化疗的62岁女性，通过直接磷钨酸（PTA）法测得的尿酸值（150 mg/L）与尿酸酶法测得的值（40 mg/L）存在差异。超滤后，直接PTA法的阳性干扰保留在蛋白质部分，而滤液中没有。向无药物血清中添加外源性依托泊苷证实了直接PTA法存在这种干扰，但尿酸酶法或透析前的PTA技术不存在这种干扰。积极的患者管理决策通常基于高尿酸血症的严重程度。我们不建议使用直接磷钨酸法来测量接受依托泊苷治疗患者的尿酸。
